Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia

Mélanie Vivancos (1) , Roberto Fanelli , Élie Besserer-Offroy (1) , Sabrina Beaulieu (1) , Magali Chartier (1) , Martin Resua-Rojas (1) , Christine E Mona (2) , Santo Previti (3) , Emmanuelle Rémond (3) , Jean-Michel M Longpré (1) , Florine Cavelier (3) , Philippe Sarret (1)

1 UdeS - Université de Sherbrooke
2 UCLA - University of California [Los Angeles]
3 IBMM - Institut des Biomolécules Max Mousseron [Pôle Chimie Balard]

The endogenous tridecapeptide neurotensin (NT) has emerged as an important inhibitory modulator of pain transmission, exerting its analgesic action through the activation of the G protein-coupled receptors, NTS1 and NTS2. Whereas both NT receptors mediate the analgesic effects of NT, NTS1 activation also produces hypotension and hypothermia, which may represent obstacles for the development of new pain medications. In the present study, we implemented various chemical strategies to improve the metabolic stability of the biologically active fragment NT(8− 13) and assessed their NTS1/NTS2 relative binding affinities. We then determined their ability to reduce the nociceptive behaviors in acute, tonic, and chronic pain models and to modulate blood pressure and body temperature. To this end, we synthesized a series of NT(8− 13) analogs carrying a reduced amide bond at Lys 8-Lys 9 and harboring site-selective modifications with unnatural amino acids, such as silaproline (Sip) and trimethylsilylalanine (TMSAla). Incorporation of Sip and TMSAla respectively in positions 10 and 13 of NT(8− 13) combined with the Lys 8-Lys 9 reduced amine bond (JMV5296) greatly prolonged the plasma half-life time over 20 h. These modifications also led to a 25-fold peptide selectivity toward NTS2. More importantly, central delivery of JMV5296 was able to induce a strong antinociceptive effect in acute (tail-flick), tonic (formalin), and chronic inflammatory (CFA) pain models without inducing hypothermia. Altogether, these results demonstrate that the chemically-modified NT(8− 13) analog JMV5296 exhibits a better therapeutic profile and may thus represent a promising avenue to guide the development of new stable NT agonists and improve pain management.

Domaines: Pharmacologie; Neurobiologie

Mélanie Vivancos, Roberto Fanelli, Élie Besserer-Offroy, Sabrina Beaulieu, Magali Chartier, et al.. Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. Behavioural Brain Research, 2021, 405, pp.113189. ⟨10.1016/j.bbr.2021.113189⟩. ⟨hal-03155317⟩